{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-23-000085","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.860125+00:00","generated_at":"2026-06-07T08:56:29.611904+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pacira appoints Frank D. Lee as CEO effective Jan 2, 2024; Stack retires to advisory role","bullets":["Frank Lee named CEO and Board member, effective Jan 2, 2024; prior CEO of Forma Therapeutics.","David Stack retires as CEO and Chairman, remains as advisor through August 2025.","Paul Hastings, Lead Independent Director, elected Chair of the Board effective Jan 2, 2024.","Lee's compensation: $900k base salary, 85% bonus target, 692,512 options, 99,520 RSUs as inducement awards.","Pacira Amended 2014 Inducement Plan to reserve 817,093 shares; term extended to Dec 20, 2033."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-23-000085","json":"https://secwatch.observer/filing/0001396814-23-000085.json","markdown":"https://secwatch.observer/filing/0001396814-23-000085.md","text":"https://secwatch.observer/filing/0001396814-23-000085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000085/0001396814-23-000085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000085/pcrx-20231220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T08:56:29.611904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca1f26e4c4","claim":"David Stack retired as Chief Executive Officer at Pacira BioSciences, Inc..","evidence_excerpt":"David Stack informed the Board of Directors (the \"Board\") of Pacira BioSciences, Inc. (the \"Company\") that he intended to retire as Chief Executive Officer of the Company and as a member of the Board effective immediately following the appointment of his successor as Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000085/0001396814-23-000085-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"dc91ab2919","claim":"Frank Lee was appointed as Chief Executive Officer at Pacira BioSciences, Inc..","evidence_excerpt":"the Board appointed Frank Lee as Chief Executive Officer of the Company and as a member of the Board, effective January 2, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681423000085/0001396814-23-000085-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}